Pharmaceutical 5694 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Fuji film pulls four duodenoscopes from market due to health risk


Fujifilm Medical Systems is removing four older models of specialized endoscopes known as duodenoscopes in the United States due to known safety risks to patients, according to a Food and Drug Administration Safety Alert. The company announced that it plans to remove models ED-250XL5, ED-250XT5, ED-450XL5, and ED-450XT5 duodenoscopes in the U.S., which are only currently in use in a “limited number” of medical centers. Fujifilm said the move was purely a “business decision” and that it would be providing its U.S. customers with its more recent model of duodenoscope, the ED-530XT. Duodenoscopes are devices that are threaded down the ... Read More

Sanofi tries to squelch whistleblower in Taxotere case, Judge rejects arguments

bald woman, Taxotere - Pixabay image

Taxotere is facing multidistrict litigation (MDL) from hundreds of plaintiffs who accuse French pharmaceutical company Sanofi-Aventis of illegally, untruthfully marketing Taxotere as superior to similar competing drugs, while concealing from American consumers that the drug caused permanent hair loss. Since 2005, the drug came with a warning that it could cause permanent alopecia in Europe and Canada, but it wasn’t until 2015 that the label in the United States was changed to reflect this risk. In addition to these suits the drug manufacturer is also accused in a whistleblower lawsuit of falsely marketing Taxotere and providing doctors with illegal kickbacks ... Read More

Nostalgic baby powder use goes against doctors’ recommendations

talc ovarian cancer

USA Today asks the question, “Amid concerns, why do we even have baby powder any more?” Johnson’s Baby Powder has been the subject of international concern as American juries last year found the product responsible for three different women’s ovarian cancer and ordered the pharmaceutical giant to pay nearly $200 million to the victims and their families. Johnson and Johnson continues to publicly tout its products’ safety, refusing to take talc products off the shelves. USA Today points out that with so many alternatives to talc, which are considered to be safer, such as cornstarch products, talc has already largely ... Read More

Woman’s body detox leaves her with severe, life threatening side effects

supplement - Jack3d

The New Year brings new resolutions for consumers to take better care of their bodies, and increasing in popularity are body detox regimens designed to rid the blood and organs of impurities. But a case study published in the British Medical Journal cautions consumers about the potential risks associated with herbal supplements that promise to detoxify. The case study involves that of a healthy, physically fit, 47-year-old woman who was taken to the hospital because she was acting confused and repeating behaviors. She later collapsed and suffered a seizure. She reported having taken a variety of herbal supplements on a regular ... Read More

Eliquis sales poised to top Xarelto in blood thinner market


Bristol-Myers Squibb (BMS) and Pfizer’s blood thinner Eliquis is poised to edge ahead of Johnson & Johnson’s Janssen Pharmaceuticals and Bayer’s Xarelto in 2017 and become the market leader. BMS CEO Giovanni Caforio added, “We think we are relatively close to achieving that.” Eliquis has already nabbed the top spot in the institutional setting, such as in hospitals and cardiologists’ offices, beating out long-used warfarin, and is making ground among primary care physicians. “We are beginning to see very, very strong momentum,” Caforio added. Xarelto and Eliquis were approved by the Food and Drug Administration (FDA) in 2011 and 2012, ... Read More

Woman hopes to encourage confidence in others with hair loss, Asks Apple for bald emoji

bald girl emoji - courtesy BaldGirlEmojiTC via Twitter

Alopecia areata is an autoimmune disease that causes hair loss, when the immune system attacks hair follicles on the face, scalp and sometimes other areas of the body. It can be brought on by severe stress. Hair often falls out in patches but in can result in complete baldness. According to Nasdaq, two-thirds of those affected by the disease are younger than 30 years old when their hair loss begins. It is often emotionally devastating. “Kids are pretty cruel, they speak their mind and at the time I had wigs that were synthetic, which looked pretty tragic,” Sarah Christian told ... Read More

Large-Diameter Metal-on-Metal Hips Sparked Study on Metal Allergy

metal on metal hip parts

A Missouri orthopedic surgeon and colleagues have initiated a study that identifies the patients who underwent total joint replacement reporting a metal allergy. The study analyzes the effect of voluntary reported metal allergies on the clinical outcomes following the surgery. Dr. Denis Nam, recipient of the Orthopaedic Research and Education/Current Concepts of Joint Replacement (CCJR) Clinical Award Paper, along with other researchers, gathered retrospective data from 589 patients who received total knee arthroplasty (TKA), and 906 patients who received total hip arthroplasty between the years of 2009 and 2011. Before January 2010, the incidence of self-reported metal allergy was 1.7 percent. After January 2010, the incidence was 4 percent. ... Read More

Talc on Consumer Safety’s list of harmful ingredients in baby care products

talc ovarian cancer starts out the new year by warning its readers about harmful ingredients in baby care products. The site encourages readers to be aware that just because a product smells good, doesn’t mean it’s a good idea to use it on their baby. Readers are encouraged to reduce amount of chemicals they’re putting on their babies’ developing bodies, especially when some ingredients are linked to serious health problems. Reading labels and shopping for more natural baby products, simply minimizing the use of skin care products for infants such as oils, lotions and shampoos, and keeping plastic toys out of children’s ... Read More

FDA issues draft guidance for OTC aspirin manufacturers promoting heart benefits


The Food and Drug Administration (FDA) wants makers of over-the-counter aspirin-containing products that use heart-related images on their labels or packaging to add an advisory instructing patients to consult with their doctors before taking an aspirin for cardiovascular conditions. Some medical groups, such as the U.S. Preventative Services Task Force, recommend people ages 50 to 69 take a low-dose aspirin if they are at risk for cardiovascular disease in order to lower their risk. However, some medical groups shy away from this recommendation because daily aspirin therapy can lead to other health problems, including gastrointestinal bleeds, brain bleeds, kidney failure ... Read More

Plaintiffs ask judge not to transfer Invokana side effects lawsuits to NJ


More than 100 people suing Johnson & Johnson and Janssen Pharmaceuticals over kidney damage allegedly caused by the companies’ diabetes drug Invokana are asking a Pennsylvania federal judge not to transfer their cases to a recently established multidistrict litigation (MDL) in New Jersey, arguing doing so would go against common logic. Johnson & Johnson and its unit Janssen filed a motion last November to stay and transfer or dismiss 106 of the 143 cases that had been filed in Pennsylvania Court of Common Pleas and later removed to the U.S. District Court for the Eastern District of Pennsylvania. Plaintiffs argue ... Read More